Business Context and Reporting Period
Company: BioLife Solutions, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2008
Business Overview: BioLife develops and sells preservation solutions (HypoThermosol and CryoStor) designed to maintain the viability of cellular matter and tissues during freezing, transportation, and storage. The company serves the biotechnology and medical communities, including cell therapy, cord blood banking, and organ transplantation sectors.
Key Financial Metrics
| Metric | Q1 2008 | Q1 2007 |
|---|---|---|
| Total Revenue | $317,634 | $207,488 |
| Gross Margin | $159,232 (50%) | $105,968 (51%) |
| Operating Loss | $(560,614) | $(582,270) |
| Net Loss | $(645,527) | $(591,530) |
| Cash and Cash Equivalents (End of Period) | $136,182 | $288,677 |
| Net Cash Used in Operating Activities | $(516,995) | $(527,401) |
| Long-Term Debt (Related Parties) | $3,463,127 | $2,750,000 |
| Stockholders' Equity (Deficiency) | $(3,089,522) | $(2,469,790) |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 53% year-over-year, driven by a 48% increase in product sales ($306,384 vs. $207,488) and the addition of $11,250 in licensing revenue.
- Expense Increases:
- R&D Expenses: Surged 196% to $111,302 due to increased headcount, travel, and legal fees related to intellectual property.
- Interest Expense: Rose significantly to $45,418 from $9,503 due to higher average debt balances.
- Expense Decreases: Sales and marketing expenses dropped 36% to $96,086, primarily due to reduced headcount and travel costs.
- Debt Position: Long-term promissory notes payable to related parties increased by approximately $713,000, reflecting new draws on a Secured Convertible Multi-Draw Term Loan Facility.
Outlook, Risks, and Management Commentary
- Liquidity and Going Concern: Management states that current cash and access to the Multi-Draw Term Loan Note should provide sufficient funds through December 31, 2008. However, the filing includes a "going concern" warning. If revenue forecasts fail, costs exceed projections, or litigation outcomes are adverse, the company may require immediate additional capital.
- Financing Risks: There is no assurance that existing investors will continue to provide capital or that new financing will be available on non-dilutive terms. Failure to secure capital could prevent the company from continuing operations.
- Legal Contingencies: General and administrative expenses increased due to legal fees associated with litigation filed by and against the company. An adverse outcome could impact financial stability.
- Debt Structure: The new loan facility is secured by all company assets and includes a conversion feature into equity in the event of a bona fide financing of at least $2 million.
Investor Verification Checklist
- Cash Runway: Verify if the company has drawn the full $768,436.70 commitment available under the Multi-Draw Term Loan Note and the current status of remaining availability.
- Litigation Status: Review the specific nature and potential financial exposure of the litigation mentioned as a driver for increased legal fees.
- Revenue Sustainability: Assess the concentration of the new customers in the cell therapy and cord blood markets driving the 48% revenue increase.
- Debt Covenants: Examine the terms of the Secured Convertible Multi-Draw Term Loan Note for any restrictive covenants or default triggers.
- Capital Needs: Confirm if the company has initiated discussions for additional equity financing to extend operations beyond the projected December 2008 date.